Viatris宣布批准基于减排目标的科学目标计划(SBTi)

1月26日,匹兹堡2023 / 3提单媒体/—Viatris Inc .)(纳斯达克:录像机),全球医疗保健公司,今天宣布,其近期科学减排目标已经批准的计划(SBTi)基于科学的目标。SBTi是一个全球性的身体使企业制定雄心勃勃的减排目标符合最新的气候科学。

Viatris总统拉吉夫·马利克说:“这SBTi批准标志着一个重要的里程碑Viatris持续致力于可持续的业务。我们定期监控我们的进展,评估每年温室气体减排和减排策略。我们致力于减少我们对环境的影响,同时维护一个可靠的供应。”

Viatris宣布首次全公司可持续发展目标,包括环保目标,今年早些时候。金博宝怎么注册SBTi Viatris分类的范围1和2的目标雄心和确定它符合1.5°C的轨迹,在全球范围内限制全球变暖的目标。公司的气候目标:

• Viatris致力于减少绝对范围1和2温室气体排放量从2020年到2030年的42%。* Viatris公司还致力于减少绝对范围3温室气体排放购买商品和服务、资本货物、燃料和能源相关的活动,和上游运输和分布在同一时间的25%。188bet上不了
  *目标边界包括土地相关排放和删除从生物能源原料。

这些努力包括系统工作减少碳排放,增加可再生能源的使用,提高效率在我们自己的运作和与合作伙伴合作,鼓励他们的努力。我们也正在努力保护我们的员工和业务从气候变化的影响通过有效的计划、风险缓解和构建弹性对极端天气的影响,并提供或部署适当的技术和过程,以确保对气候的影响最小。

Viatris公司事务主管劳拉Ramsburg说,“通过我们的专注和热情的全球劳动力,Viatris正在验证的重要进展目标SBTi支持我们的承诺,持续提供高质量的药品。因为环境和人类健康是相互联系的,缓解和适应气候变化的关键部件保护我们供应链的弹性,我们提供病人的健康和福祉,我们所依赖的社区。”

CDP SBTi是一个伙伴关系,联合国全球契约,世界资源研究所(WRI)和世界自然基金会(WWF)。SBTi行动呼吁是我们意味着商业联盟的承诺。计划定义和促进最佳实践在科学目标设置,提供资源和指导,以减少障碍采用和独立评估和批准公司的目标。

作为全球医疗保健公司,可持续性是Viatris业务的核心和目的。金博宝怎么注册更多地了解Viatris的努力以及公司与利益相关者在整个 全球 的解决一些世界上最紧迫的健康, 环境和社会问题,请阅读公司的 2021年金博宝怎么注册可持续发展报告,概述了公司2021年进步,成就和承诺在关键领域包括访问和全球卫生、员工、环境管理和社区的参与。188bet网址怎么打不开

关于 Viatris 
Viatris公司(纳斯达克:录像机)是一个全球性的医疗保健公司全球让人生活更健康在生命的每个阶段。我们提供的药品,推进可持续运营,开发创新的解决方案和利用我们的集体专长,连接更多的人更多的产品和服务通过我们独一无二的全球医疗网关®。188bet上不了成立于2020年11月,Viatris汇集了科学、制造和分销专业知识与证明监管,医疗和商业功能交付高质量的药物给病人在165多个国家和地区。Viatris”投资组合包含超过1400个批准分子跨广泛的治疗领域,生成非传染性和传染性疾病,包括全球公认的品牌,复杂的泛型和品牌药物,和各种非处方药消费产品。与全球近37000的同事,Viatris总部设在美国在匹兹堡,与全球中心、上海和海得拉巴,印度。学习更多在viatris.com和investor.viatris.com在Twitter上,联系我们@ViatrisInc,LinkedIn和YouTube。

前瞻性陈述
这个新闻稿包含语句构成“前瞻性陈述”。These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements about sustainability initiatives; Viatris' commitment to minimizing our impact on the environment while safeguarding a reliable supply of medicine; Viatris' commitment to reducing absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2020 base year and reducing absolute scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy related activities, and upstream transportation and distribution 25% within the same timeframe. Factors that could cause or contribute to such differences include, but are not limited to: our other strategic initiatives, including potential and completed divestitures, and restructuring initiatives may not achieve their intended benefits within the expected timeframe or at all; the implementation of our global restructuring initiatives and integration activities being more difficult, time consuming or costly than expected, or being unsuccessful; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.

源Viatris公司。

为进一步的信息:联系人:媒体:+ 1.724.514.1968 Communications@viatris.com;詹妮弗·莫尔,Jennifer.Mauer@viatris.com;马特·克莱恩,Matthew.Klein@viatris.com;投资者:+ 1.412.707.2866 InvestorRelations@viatris.com;比尔Szablewski, William.Szablewski@viatris.com